Opin vísindi

Re-evaluation of neohesperidine dihydrochalcone (E 959) as a food additive

Re-evaluation of neohesperidine dihydrochalcone (E 959) as a food additive

Title: Re-evaluation of neohesperidine dihydrochalcone (E 959) as a food additive
Author: EFSA Panel on Food Additives and Flavourings (FAF)
Date: 2022-11
Language: English
Department: Faculty of Food Science and Nutrition
Series: EFSA Journal; 20(11)
ISSN: 1831-4732
DOI: https://doi.org/10.2903/j.efsa.2022.7595
Subject: E 959; food additive; neohesperidine dihydrochalcone; sweetener; Parasitology; Food Science; Microbiology; Animal Science and Zoology; Veterinary (miscellaneous); Plant Science
URI: https://hdl.handle.net/20.500.11815/4404

Show full item record


EFSA Panel on Food Additives and Flavourings (FAF) 2022 , ' Re-evaluation of neohesperidine dihydrochalcone (E 959) as a food additive ' , EFSA Journal , vol. 20 , no. 11 , e07595 . https://doi.org/10.2903/j.efsa.2022.7595


The present opinion deals with the re-evaluation of neohesperidine dihydrochalcone (E 959) when used as a food additive. It is obtained by catalytic hydrogenation of a flavanone – neohesperidine – which is naturally occurring and thus isolated by alcohol extraction in bitter oranges (Citrus aurantium). Based on in vivo data in rat, neohesperidine dihydrochalcone is likely to be absorbed, also in humans, and to become systemically available. It does not raise a concern regarding genotoxicity. The toxicity data set consisted of studies on subchronic and prenatal developmental toxicity. No human studies were available. The data set was considered sufficient to derive a new acceptable daily intake (ADI). Based on the weight of evidence (WoE) analysis, the Panel considered unlikely that neohesperidine dihydrochalcone would lead to adverse effects on health in animals in the dose ranges tested. The Panel also considered that a carcinogenicity study was not warranted and that the lack of human data did not affect the overall confidence in the body of evidence. The Panel derived an ADI of 20 mg/kg bodyweight (bw) per day based on a no observed adverse effect level (NOAEL) of 4,000 mg/kg bw per day from a 13-week study in rat, applying the standard default factors of 100 for inter- and intraspecies differences and of 2 for extrapolation from subchronic to chronic exposure. For the refined brand-loyal exposure assessment scenario, considered to be the most appropriate for the risk assessment, the exposure estimates at the mean ranged from < 0.01 to 0.09 mg/kg bw per day and at the 95th percentile (P95) from 0.01 to 0.24 mg/kg bw per day. Considering the derived ADI of 20 mg/kg bw per day, the exposure estimates were below the reference value in all age groups. Therefore, the Panel concluded that dietary exposure to the food additive neohesperidine dihydrochalcone (E 959) at the reported uses and use levels would not raise a safety concern.


Publisher Copyright: © 2022 Wiley-VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

Files in this item

This item appears in the following Collection(s)